Your browser doesn't support javascript.
Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies.
Bertram, Sebastian; Pfab, Thiemo; Albert, Christian; Schmidt, Sven; Passfall, Jürgen; Haesner, Martin; Seidel, Maximilian; Hölzer, Bodo; Seibert, Felix S; Doevelaar, Adrian; Rohn, Benjamin; Zgoura, Panagiota; Babel, Nina; Westhoff, Timm H.
  • Bertram S; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Pfab T; MVZ Diaverum Potsdam, Potsdam, Germany.
  • Albert C; MVZ Diaverum Potsdam, Potsdam, Germany.
  • Schmidt S; Dialyse Praxis Fürstenwalde, Fürstenwalde, Germany.
  • Passfall J; Dialyse Praxis Königs Wusterhausen, Königs Wusterhausen, Germany.
  • Haesner M; Nierenzentrum Charlottenburg, Berlin, Germany.
  • Seidel M; Nierenzentrum Charlottenburg, Berlin, Germany.
  • Hölzer B; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Seibert FS; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Doevelaar A; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Rohn B; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Zgoura P; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Babel N; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
  • Westhoff TH; Center for Translational Medicine, University Hospital Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.
Ther Apher Dial ; 26(6): 1289-1295, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1764858
ABSTRACT

BACKGROUND:

Low-density lipoprotein apheresis is not specific to lipoproteins but removes immunoglobulins as well. It remains elusive, whether protective SARS-CoV-2 antibodies after vaccination from COVID-19 are eliminated as well.

METHODS:

A cross-sectional case-control study on 55 patients undergoing weekly lipoprotein apheresis and 21 patients with comparable comorbidities and epidemiology not undergoing apheresis. SARS-CoV-2 IgG was assessed in all patients prior to apheresis and in 38 patients both before and after apheresis.

RESULTS:

SARS-CoV-2 IgG concentrations before a session of lipoprotein apheresis were comparable to control patients not undergoing apheresis(1727 IU/ml, IQR 365-2500) vs. 1652 IU/ml,(IQR408.8-2500), p = 0.78). SARS-CoV-2 IgG concentrations were reduced by lipoprotein apheresis from 1656 IU/ml(IQR 540.5-2500) prior to 1305 IU/ml (IQR 449-2500) afterwards(p < 0.0001).

CONCLUSION:

Lipoprotein apheresis removes SARS-CoV-2 IgG. The average elimination rate was 21.2%. In the present population of patients undergoing apheresis once weekly, however, the elimination did not lead to inferior concentrations compared to patients not undergoing lipoprotein apheresis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Component Removal / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Ther Apher Dial Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: 1744-9987.13842

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Component Removal / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Ther Apher Dial Journal subject: Hematology Year: 2022 Document Type: Article Affiliation country: 1744-9987.13842